Kodiak Sciences Stock Surges 128% on Positive Phase 3 Eye Disease Trial Results

Key points

• Kodiak Sciences stock rose 128% to $72.99 after positive Phase 3 trial data.
• Zenkuda met primary vision endpoints with a p-value of 0.0007.
• The company plans to submit a multi-indication biologics license application in Q4 2026.
• Zenkuda demonstrated a 0% intraocular inflammation rate and lower cataract rates than aflibercept.
• Kodiak will compete with biosimilars and branded rivals like Eylea HD and Vabysmo.

Background

Kodiak Sciences previously halted development of Zenkuda in 2023 due to an unexpected increase in cataracts but resumed trials later that year based on non-proliferative diabetic retinopathy data. This latest success follows a renewed late-phase program that has advanced the company to the cusp of an FDA filing.

How outlets are covering it

Yahoo Finance and Investing.com emphasized the massive stock surge (up to 90% premarket, 128% at open) and the positive p-values for both Zenkuda and tabirafusp-ted. Fierce Biotech highlighted the competitive landscape, noting that aflibercept patents have expired, leading to biosimilar competition, and that Kodiak will face branded rivals like Regeneron’s Eylea HD and Roche’s Vabysmo. Fierce Biotech also noted that the press release focused more on Zenkuda than tabirafusp, despite both meeting primary endpoints.

Why it matters

The positive trial results position Kodiak Sciences to seek FDA approval for Zenkuda in Q4 2026, potentially establishing a new competitor in the anti-VEGF eye disease market. The stock surge reflects investor optimism about the drug's efficacy and safety profile, despite competitive challenges from biosimilars and established branded therapies.

What to watch

Kodiak Sciences plans to submit a multi-indication biologics license application for Zenkuda in Q4 2026, including results from five Phase 3 studies across wet AMD, diabetic retinopathy, and retinal vein occlusion. The company also plans to report Phase 3 results from its first macular edema secondary to inflammation study of KSI-101 in December 2026 and is advancing tabirafusp-ted in diabetic macular edema through its ongoing Phase 3 ALTO pivotal program.